4.8 Article

Orally deliverable strategy based on microalgal biomass for intestinal disease treatment

Journal

SCIENCE ADVANCES
Volume 7, Issue 48, Pages -

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/sciadv.abi9265

Keywords

-

Funding

  1. National Key Research and Development Program of China [2018YFC0115701]
  2. National Natural Science Foundation of China [81671748]
  3. Key Research and Development Project of Zhejiang Province [2020C03035]
  4. U.S. METAvivor Early Career Investigator Award [2018A020560]
  5. Harvard Medical School/Brigham and Women's Hospital Basic Scientist Grant [2420 BPA075]
  6. Center for Nanomedicine Research Fund [2019A014810]

Ask authors/readers for more resources

The innovative strategy of oral drug delivery using a formulation based on Spirulina platensis loaded with curcumin shows promise for treating intestinal diseases. The formulation not only improves drug bioavailability but also demonstrates excellent antitumor and anti-inflammatory efficacy.
Design of innovative strategies for oral drug delivery is particularly promising for intestinal disease treatment. However, many obstacles such as poor therapeutic efficacy and low bioavailability and biocompatibility remain to be addressed. Here, we report a versatile formulation based on a helical-shaped cyanobacterium, Spirulina platensis (SP), loaded with curcumin (SP@Curcumin) for the treatment of colon cancer and colitis, two types of intestinal diseases. In radiotherapy for colon cancer, SP@Curcumin could mediate combined chemo- and radiotherapy to inhibit tumor progression while acting as a radioprotector to scavenge reactive oxygen species induced by the high dose of x-ray radiation in healthy tissues. SP@Curcumin could also reduce the production of proinflammatory cytokines and thereby exerted anti-inflammatory effects against colitis. The oral drug delivery system not only leveraged the biological properties of microalgal carriers to improve the bioavailability of loaded drugs but also performed excellent antitumor and anti-inflammation efficacy for intestinal disease treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available